Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Approval For ViiV’s ‘Last Resort’ HIV Drug Rukobia

Attachment Inhibitor Aimed At Heavily Pre-Treated Patients

Executive Summary

The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.

You may also be interested in...



HIV Therapies: Maturation Inhibitor R&D Bears Fruit At ViiV Healthcare

A potent HIV maturation inhibitor has entered Phase IIb at ViiV Healthcare, in combination studies with other antiretrovirals, as the latest potential first-in-class agent to move along the company’s pipeline.

Gilead’s Lenacapvir May Offer Twice-Yearly HIV Salvage Therapy

A first-in-class capsid inhibitor for HIV, lenacapavir has produced strong efficacy data for viral load reduction in treatment-experienced patients. The data measure up well against Viiv’s Rukobia, analyst says.

FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen

ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel